A phase II study of diaziquone in children with recurrent or progressive solid tumors. Report from the Childrens Cancer Study Group.

Abstract

Seventy-two children with recurrent, progressive, or metastatic lymphomas and other solid tumors, exclusive of primary central nervous system (CNS) tumors, were treated with aziridinylbenzoquinone (AZQ, diaziquone) at 9 mg/m2/day by 30-min intravenous infusion for 5 days every 3 weeks. Fifty-four patients were evaluable for response. Three partial responses occurred, two in patients with recurrent Hodgkin's disease and one in a patient with intraocular retinoblastoma. Sufficient numbers of patients with osteosarcoma, neuroblastoma, and Wilms' tumor were evaluable to demonstrate inactivity of this dosing regimen in these tumor types. Numbers of evaluable patients for other tumor types were insufficient to conclusively demonstrate inactivity. Myelosuppression, which was profound and prolonged, was observed. As administered in this study, AZQ has marginal activity and severe myelotoxicity in children with solid tumors.

• Authors: L J Ettinger, N Ru, M D Krailo, K S Ruccione, W A Krivit, G D Hammond
• Journal: The American journal of pediatric hematology/oncology (Am J Pediatr Hematol Oncol) Vol. 12 Issue 3 Pg. 301-5 ( 1990) ISSN: 0192-8562 [Print] United States
• PMID: 2240475 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Aziridines
• Benzoquinones
• diaziquone

Topics

• Adolescent
• Adult
• Antineoplastic Agents (adverse effects, therapeutic use)
• Aziridines (adverse effects, therapeutic use)
• Benzoquinones (adverse effects, therapeutic use)
• Bone Marrow Diseases (chemically induced)
• Child
• Child, Preschool
• Drug Evaluation
• Humans
• Infant
• Lymphoma (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Neoplasms (drug therapy)